Update: Krystal Biotech Q3 Net Income Falls, Revenue Rises

08:41 AM EST, 11/02/2026 (MT Newswires) -- (Updates with analysts' estimate in the second paragraph, buyback details in the fifth paragraph and latest stock move in the last paragraph.) Krystal Biotech (KRYS) reported Q3 net income Monday of $2.05 per diluted share, compared with $2.66 a year earlier. Analysts polled by FactSet expected $1.79. Net product revenue for the quarter ended Sept. 30 was $127.3 million, compared with $97.8 million a year earlier. Analysts polled by FactSet expected $125.8 million. The company's board authorized a $400 million share repurchase program with no expiration date. The company's shares were down 5.5% in recent premarket activity.